Clinical Trials Logo

Clinical Trial Summary

This phase I trial studies the side effects and best dose of WEE1 inhibitor MK-1775 (AZD1775) when given together with cisplatin and radiation therapy in treating patients with cervical cancer. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells. Giving WEE1 inhibitor MK-1775 together with cisplatin and radiation therapy may be a better treatment for patients with cervical cancer.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose (RP2D) and safety profile of AZD1775 (MK-1775) in combination with cisplatin and radiation in patients with cervical cancer (phase I).

SECONDARY OBJECTIVES:

I. To evaluate the pharmacodynamic effects of AZD1775 (MK-1775) drugs when administered in combination with cisplatin and radiation (in particular, for the 15 patients treated in an expansion cohort at the RP2D). Pharmacodynamic biomarkers will include: phosphorylated cell division cycle protein 2 homolog (pCDC2), antigen Ki-67 (Ki67), gamma H2A histone family, member X (gH2AX), phosphorylated (phospho)-histone 3 (pH3), and cleaved caspase-3 (CC3).

II. To obtain preliminary information about the progression-free survival of AZD1775 (MK-1775) in combination with standard radiation and chemotherapy in women with locally advanced high-risk cervix cancer.

III. To determine the acute and late toxicity of AZD1775 (MK-1775) when administered to patients with cervix cancer in combination with standard radiation and concurrent chemotherapy.

IV. To correlate the serum pharmacokinetic parameters—maximum concentration (Cmax), time to peak concentration (Tmax), 8-hours concentration (C8), and area under the curve (AUC) (0-8)—with the drug concentration in the tumor tissue (for patients in the expansion cohort).

OUTLINE: This is a dose-escalation study of WEE1 inhibitor MK-1775. Patients are assigned to 1 of 3 treatment groups.

COHORT I: Patients receive WEE1 inhibitor MK-177 orally (PO) twice daily (BID) on days 1-2, 8-9, 15-16, 22-23, and 29-30.

COHORT II: Patients receive WEE1 inhibitor MK-177 PO BID on days 4-5, 11-12, 18-19, 25-26, and 32-33 or on days 3-5, 10-12, 17-19, 24-26, and 31-33.

COHORT III: Patients receive WEE1 inhibitor MK-177 PO BID on days 1-5, 8-12, 15-19, 22-26, and 29-33.

In all cohorts, patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, and 29 and undergo of pelvic external beam radiation therapy 5 days a week for 5 weeks followed by pulsed-dose rate or high-dose rate brachytherapy 5 days a week in weeks 6-8.

After completion of study treatment, patients are followed up at 4 weeks, at 3, 6, and 12 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01958658
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Suspended
Phase Phase 1
Start date September 5, 2013

See also
  Status Clinical Trial Phase
Completed NCT00416455 - Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Phase 1/Phase 2
Completed NCT00054444 - Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Phase 1
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01764802 - Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Phase 2
Completed NCT00068549 - Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Phase 1
Completed NCT00559377 - FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Phase 2
Recruiting NCT03469531 - Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer Phase 2
Completed NCT00897442 - Collecting Tumor Samples From Patients With Gynecological Tumors N/A
Completed NCT01098630 - Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
Completed NCT00941070 - Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Phase 2
Withdrawn NCT01019278 - Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes Phase 2
Completed NCT00104910 - Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Phase 1
Terminated NCT00262821 - Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Phase 3
Completed NCT00107445 - EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer Phase 2
Terminated NCT01992861 - MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
Terminated NCT00577317 - Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Phase 3
Completed NCT00017004 - Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Phase 3
Completed NCT03198286 - Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors N/A
Active, not recruiting NCT01835171 - Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer Phase 2
Completed NCT00460356 - Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes N/A